1887

Abstract

A DNA vaccine expressing human immunodeficiency virus type 1 (HIV-1) southern African subtype C Gag (pTHGag) and a recombinant baculovirus Pr55 virus-like particle prepared using a subtype C Pr55 protein (Gag VLP) was tested in a prime–boost inoculation regimen in Chacma baboons. The response of five baboons to Gag peptides in a gamma interferon (IFN-) enzyme-linked immunospot (ELISPOT) assay after three pTHGag immunizations ranged from 100 to 515 spot-forming units (s.f.u.) per 10 peripheral blood mononuclear cells (PBMCs), whilst the response of two baboons to the Gag VLP vaccine ranged from 415 to 465 s.f.u. per 10 PBMCs. An increase in the Gag-specific response to a range of 775–3583 s.f.u. per 10 PBMCs was achieved by boosting with Gag VLPs the five baboons that were primed with pTHGag. No improvement in Gag responses was achieved in this prime–boost inoculation regimen by increasing the number of pTHGag inoculations to six. IFN- responses were mapped to several peptides, some of which have been reported to be targeted by PBMCs from HIV-1 subtype C-infected individuals. Gag VLPs, given as a single-modality regimen, induced a predominantly CD8 T-cell IFN- response and interleukin-2 was a major cytokine within a mix of predominantly Th1 cytokines produced by a DNA–VLP prime–boost modality. The prime–boost inoculation regimen induced high serum p24 antibody titres in all baboons, which were several fold above that induced by the individual vaccines. Overall, this study demonstrated that these DNA prime/VLP boost vaccine regimens are highly immunogenic in baboons, inducing high-magnitude and broad multifunctional responses, providing support for the development of these products for clinical trials.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83501-0
2008-09-01
2019-11-13
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/9/2214.html?itemId=/content/journal/jgv/10.1099/vir.0.83501-0&mimeType=html&fmt=ahah

References

  1. Allen, T. M., Vogel, T. U., Fuller, D. H., Mothé, B. R., Steffen, S., Boyson, J. E., Shipley, T., Fuller, J., Hanke, T. & other authors ( 2000; ). Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 164, 4968–4978.[CrossRef]
    [Google Scholar]
  2. Amara, R. R., Villinger, F., Altman, J. D., Lydy, S. L., O'Neil, S. P., Staprans, S. I., Montefiori, D. C., Xu, Y., Herndon, J. G. & other authors ( 2001; ). Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69–74.[CrossRef]
    [Google Scholar]
  3. Amara, R. R., Patel, K., Niedziela, G., Nigam, P., Sharma, S., Staprans, S. I., Montefiori, D. C., Chenareddi, L., Herndon, J. G. & other authors ( 2005; ). A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease. J Virol 79, 15356–15367.[CrossRef]
    [Google Scholar]
  4. Anthony, D. D. & Lehmann, P. V. ( 2003; ). T-cell epitope mapping using the ELISPOT approach. Methods 29, 260–269.[CrossRef]
    [Google Scholar]
  5. Barouch, D. H., Santra, S., Schimtz, J. E., Kuroda, M. J., Fu, T. M., Wagner, W., Bilska, M., Craiu, A., Zheng, X. X. & other authors ( 2000; ). Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486–492.[CrossRef]
    [Google Scholar]
  6. Boyer, J. D., Ugen, K. E., Wang, B., Agadjanyan, M., Gilbert, L., Bagarazzi, M. L., Chattergoon, M., Frost, P., Javadian, A. & other authors ( 1997; ). Protection of chimpanzees from high dose heterologous HIV-1 challenge by DNA vaccination. Nat Med 3, 526–532.[CrossRef]
    [Google Scholar]
  7. Boyer, J. D., Cohen, A. D., Vogt, S., Schumann, K., Nath, B., Ahn, L., Lacy, K., Bagarazzi, M. L., Higgins, T. J. & other authors ( 2000; ). Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of β-chemokines. J Infect Dis 181, 476–483.[CrossRef]
    [Google Scholar]
  8. Boyer, J. D., Robinson, T. M., Maciag, P. C., Peng, X., Johnson, R. S., Pavlakis, G., Lewis, M. G., Shen, A., Siliciano, R. & other authors ( 2005; ). DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. Virology 333, 88–101.[CrossRef]
    [Google Scholar]
  9. Calarota, S., Bratt, G., Nordlund, S., Hinkula, J., Leandersson, A. C., Sandstrom, E. & Wahren, B. ( 1998; ). Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351, 1320–1325.[CrossRef]
    [Google Scholar]
  10. Casimiro, D. R., Tang, A., Chen, T. M., Fu, T. M., Evans, R. K., Davies, M. E., Freed, D. C., Hurni, W., Aste-Amezaga, J. M. & other authors ( 2003a; ). Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77, 7663–7668.[CrossRef]
    [Google Scholar]
  11. Casimiro, D. R., Chen, L., Fu, T. M., Evans, R. K., Caulfield, M. J., Davies, M. E., Tang, A., Chen, M., Huang, L. & other authors ( 2003b; ). Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77, 6305–6313.[CrossRef]
    [Google Scholar]
  12. Chege, G. K., Williamson, A.-L., Passmore, J. S., Bourn, W., Ryffel, B. & Shephard, E. G. ( 2005; ). The immune response of the Chacma baboon to Bacille Calmette Guerin: development of a primate model for BCG-based vaccine research. Vaccine 23, 5783–5791.[CrossRef]
    [Google Scholar]
  13. Cherpelis, S., Shrivastava, I., Gettie, A., Jin, X., Ho, D. D., Barnett, S. W. & Stamatatos, L. ( 2001; ). DNA vaccination with the human immunodeficiency virus type 1 SF1ΔV2 envelope elicits immune responses that offer partial protection of CD8+ T-cell-depleted rhesus macaques. J Virol 75, 1547–1550.[CrossRef]
    [Google Scholar]
  14. Damian, R. T., Greene, N. D. & Katler, S. S. ( 1971; ). IgG subclasses of baboon (Papio cynocephalus). J Immunol 106, 246–257.
    [Google Scholar]
  15. Deml, L., Schirmbeck, R., Reimann, J., Wolf, H. & Wagner, R. ( 1997; ). Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induced cytotoxic T-cells and neutralizing antibodies. Virology 235, 26–39.[CrossRef]
    [Google Scholar]
  16. Deml, L., Wild, J. & Wagner, R. ( 2004; ). Virus-like particles: a novel tool for the induction and monitoring of both T-helper and cytotoxic T-lymphocyte activity. Methods Mol Med 94, 133–157.
    [Google Scholar]
  17. Doan, L. X., Li, M., Chen, C. & Yao, Q. ( 2005; ). Virus-like particles as HIV-1 vaccines. Rev Med Virol 15, 75–88.[CrossRef]
    [Google Scholar]
  18. Doria-Rose, N. A., Ohlen, C., Polacino, P., Pierce, C. C., Hensel, M. T., Kuller, L., Mulvania, T., Anderson, D., Greenberg, P. D. & other authors ( 2003; ). Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J Virol 77, 11563–11577.[CrossRef]
    [Google Scholar]
  19. Edwards, B. H., Bansal, A., Sabbaj, S., Bakari, J., Mulligan, M. J. & Geopfert, P. A. ( 2002; ). Magnitude of functional CD8+ T-cell responses to the Gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 76, 2298–2305.[CrossRef]
    [Google Scholar]
  20. Ellenberger, D., Wyatt, L., Li, B., Buge, S., Lanier, N., Rodriguez, I. V., Sariol, C. A., Martinez, M., Monsour, M. & other authors ( 2005; ). Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs. Virology 340, 21–32.[CrossRef]
    [Google Scholar]
  21. Estcourt, M. J., McMichael, A. J. & Hanke, T. ( 2004; ). DNA vaccines against human immunodeficiency virus type 1. Immunol Rev 199, 144–155.[CrossRef]
    [Google Scholar]
  22. Giri, M., Ugen, K. E. & Weiner, D. B. ( 2004; ). DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev 17, 370–389.[CrossRef]
    [Google Scholar]
  23. Hanke, T., Samuel, R. V., Blanchard, T. J., Neumann, V. C., Allen, T. M., Boyson, J. E., Sharpe, S. A., Cook, N., Smith, G. L. & other authors ( 1999; ). Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia Ankara boost vaccination regimen. J Virol 73, 7524–7532.
    [Google Scholar]
  24. Haynes, J. R., Fuller, D. H., Eisenbraun, M. D., Ford, M. J. & Pertmer, T. M. ( 1994; ). Accell particle-mediated DNA immunization elicits humoral, cytotoxic and protective responses. AIDS Res Hum Retroviruses 10, S43–S45.
    [Google Scholar]
  25. Hemmi, H., Kaisho, T. & Akira, S. ( 2003; ). The roles for Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 170, 3059–3064.[CrossRef]
    [Google Scholar]
  26. Huff, J. L. & Barry, P. A. ( 2003; ). B-Virus (Cercopithecine herpesvirus 1) infection in humans and macaques: potential for zoonotic disease. Emerg Infect Dis 9, 246–250.[CrossRef]
    [Google Scholar]
  27. Jaffray, A., Shephard, E., van Harmelen, J., Williamson, C., Williamson, A.-L. & Rybicki, E. P. ( 2004; ). Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice. J Gen Virol 85, 409–413.[CrossRef]
    [Google Scholar]
  28. Kiepiela, P., Ngumbela, K., Thobakgale, C., Ramduth, D., Honeyborne, I., Moodley, E., Reddy, S., de Pierres, C., Mncube, Z. & other authors ( 2007; ). CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13, 46–53.[CrossRef]
    [Google Scholar]
  29. Letvin, N. L., Montefiori, D. C., Yasutomi, Y., Perry, H. C., Davies, M. E., Lekutis, C., Alroy, M., Freed, D. C., Lord, C. I. & other authors ( 1997; ). Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A 94, 9378–9383.[CrossRef]
    [Google Scholar]
  30. Letvin, N. L., Mascola, J. R., Sun, Y., Gorgone, D. A., Buzby, A. P., Xu, L., Yang, Z. Y., Chakrabarti, B., Rao, S. S. & other authors ( 2006; ). Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312, 1530–1533.[CrossRef]
    [Google Scholar]
  31. Leung, L., Srivastava, I. K., Kan, E., Legg, H., Sun, Y., Greer, C., Montefiori, D. C., zur Megede, J. & Barnett, S. W. ( 2004; ). Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. AIDS 18, 991–1001.[CrossRef]
    [Google Scholar]
  32. Locher, C. P., Witt, S. A., Ashlock, B. M., Polacino, P., Hu, S. L., Shiboski, S., Schmidt, A. M., Agy, M. B., Anderson, D. M. & other authors ( 2004; ). Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection. Vaccine 22, 2261–2272.[CrossRef]
    [Google Scholar]
  33. Lu, S., Santoro, J. C., Fuller, D. H., Haynes, J. R. & Robinson, H. L. ( 1995; ). Use of DNAs expressing HIV-1 Env and non-infectious HIV-1 particles to raise antibody responses in mice. Virology 209, 147–154.[CrossRef]
    [Google Scholar]
  34. MacGregor, R. R., Boyer, J. D., Ugen, K. E., Lacy, K. E., Gluckman, S. J., Bagarazzi, M. L., Chattergoon, M. A., Baine, Y., Higgins, T. J. & other authors ( 1998; ). First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178, 92–100.[CrossRef]
    [Google Scholar]
  35. Martin, L. N. ( 1982; ). Chromatographic fractionation of rhesus monkey (Macaca mulatta) IgG subclasses using DEAE cellulose and protein A–sepharose. J Immunol Methods 50, 319–329.[CrossRef]
    [Google Scholar]
  36. Masemola, A. M., Mashishi, T. N., Khoury, G., Bredell, H., Paximadis, M., Mathebula, T., Barkhan, D., Puren, A., Vardas, E. & other authors ( 2004a; ). Novel and promiscuous CTL epitopes in conserved regions of Gag by individuals with early subtype C HIV type 1 infection from Southern Africa. J Immunol 173, 4607–4617.[CrossRef]
    [Google Scholar]
  37. Masemola, A., Mashishi, T., Khoury, G., Mohube, P., Mokgotho, P., Vardas, E., Colvin, M., Zijenah, L., Katzenstein, D. & other authors ( 2004b; ). Hierarchial targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol 78, 3233–3243.[CrossRef]
    [Google Scholar]
  38. Mashishi, T. & Gray, C. M. ( 2002; ). The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes. Clin Chem Lab Med 40, 903–910.
    [Google Scholar]
  39. Mattapallil, J. J., Douek, D. C., Buckler-White, A., Montefiori, D., Letvin, N. L., Nabel, G. J. & Roederer, M. ( 2006; ). Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med 203, 1533–1541.[CrossRef]
    [Google Scholar]
  40. Mergener, K., Facke, M., Welker, R., Brinkmann, V., Gelderblom, H. R. & Krausslich, H. G. ( 1992; ). Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells. Virology 186, 25–39.[CrossRef]
    [Google Scholar]
  41. Montefiori, D. C., Safrit, J. T., Lydy, S. L., Barry, A. P., Bilska, M., Vo, H. T., Klein, M., Tartaglia, J., Robinson, H. L. & Rovinski, B. ( 2001; ). Induction of neutralizing antibodies and Gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J Virol 75, 5879–5890.[CrossRef]
    [Google Scholar]
  42. Mooij, P., Nieuwenhuis, I. G., Knoop, C. J., Doms, R. W., Bogers, W. M., Ten Haaft, P. J., Niphuis, H., Koornstra, W., Bieler, K. & other authors ( 2004; ). Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection. J Virol 78, 3333–3342.[CrossRef]
    [Google Scholar]
  43. Morris, L., Williamson, C. & Vardas, E. ( 2001; ). Progress towards developing a vaccine to prevent HIV and AIDS in South Africa. S Afr Med J 91, 948–951.
    [Google Scholar]
  44. Murthy, K. K., Salas, M. T., Carey, K. D. & Patterson, J. L. ( 2006; ). Baboon as a nonhuman primate model for vaccine studies. Vaccine 24, 4622–4624.[CrossRef]
    [Google Scholar]
  45. Notka, F., Stahl-Hennig, C., Dittmer, U., Wolf, H. & Wagner, R. ( 1999; ). Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies. Vaccine 18, 291–301.[CrossRef]
    [Google Scholar]
  46. Pal, R., Wang, S., Kalyanaraman, V. S., Whitney, S., Keen, T., Hocker, L., Hudacik, L., Rose, N., Mboudjeka, I. & other authors ( 2006; ). Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 348, 341–353.[CrossRef]
    [Google Scholar]
  47. Paliard, X., Liu, Y., Wagner, R., Wolf, H., Baenziger, J. & Walker, C. M. ( 2000; ). Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses 16, 273–282.[CrossRef]
    [Google Scholar]
  48. Ramduth, D., Chetty, P., Mngquandaniso, N. C., Nene, N., Harlow, J. D., Honeyborne, I., Ntumba, N., Gappoo, S., Henry, C. & other authors ( 2005; ). Differential immunogenicity of HIV-1 clade C proteins in eliciting CD8+ and CD4+ cell responses. J Infect Dis 192, 1588–1596.[CrossRef]
    [Google Scholar]
  49. Raviprakash, K., Ewing, D., Simmons, M., Porter, K. R., Jones, T. R., Hayes, C. G., Stout, R. & Murphy, G. S. ( 2003; ). Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 315, 345–352.[CrossRef]
    [Google Scholar]
  50. Robinson, H. L., Montefiori, D. C., Johnson, R. P., Manson, K. H., Kalish, M. L., Lifson, J. D., Rizvi, T. A., Lu, S., Hu, S. L. & other authors ( 1999; ). Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 5, 526–534.[CrossRef]
    [Google Scholar]
  51. Sadagopal, S., Amara, R. R., Montefiori, D. C., Wyatt, L. S., Staprans, S. I., Kozyr, N. L., McClure, H. M., Moss, B. & Robinson, H. L. ( 2005; ). Signature for long-term vaccine-mediated control of a simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of co-producing gamma interferon and interleukin-2. J Virol 79, 3243–3253.[CrossRef]
    [Google Scholar]
  52. Sakuragi, S., Goto, T., Sano, K. & Morikawa, Y. ( 2002; ). HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 99, 7956–7961.[CrossRef]
    [Google Scholar]
  53. Smith, J. M., Amara, R. R., Campbell, D., Xu, Y., Patel, M., Sharma, S., Butera, S. T., Ellenberger, D. L., Yi, H. & other authors ( 2004; ). DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses 20, 1335–1347.[CrossRef]
    [Google Scholar]
  54. Suh, Y. S., Park, K. S., Sauermann, U., Franz, M., Norley, S., Wilfingseder, D., Stoiber, H., Fagrouch, Z., Heeney, J. & other authors ( 2006; ). Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model. Vaccine 24, 1811–1820.[CrossRef]
    [Google Scholar]
  55. UNAIDS ( 2006; ). UNAIDS/WHO AIDS Epidemic Update: December 2006. http://data.unaids.org/pub/EpiReport/2006/2006_EpiUpdate_en.pdf
  56. van Harmelen, J. H., Shephard, E., Thomas, R., Hanke, T., Williamson, A.-L. & Williamson, C. ( 2003; ). Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa. Vaccine 21, 4380–4389.[CrossRef]
    [Google Scholar]
  57. Wagner, R., Deml, L., Fliessbach, H., Wanner, G. & Wolf, H. ( 1994; ). Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology 200, 162–175.[CrossRef]
    [Google Scholar]
  58. Wagner, R., Deml, L., Schirmbeck, R., Niedrig, M., Reimann, J. & Wolf, H. ( 1996a; ). Construction, expression and immunogenicity of chimeric HIV-1 virus-like particles. Virology 220, 128–140.[CrossRef]
    [Google Scholar]
  59. Wagner, R., Deml, L., Notka, F., Wolf, H., Schirmbeck, R., Reimann, J., Teeuwsen, V. & Heeney, J. ( 1996b; ). Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques. Intervirology 39, 93–103.
    [Google Scholar]
  60. Wagner, R., Teeuwsen, V. J., Deml, L., Notka, F., Haaksma, A. G., Jhagjhoorsingh, S. S., Niphuis, H., Wolf, H. & Heeney, J. L. ( 1998; ). Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection. Virology 245, 65–74.[CrossRef]
    [Google Scholar]
  61. Whitley, R. J. & Hilliard, J. K. ( 2001; ). Cercopithecine herpesvirus (B virus). In Fields Virology, 4th edn, vol. 2, pp. 2835–2848. Edited by P. M. Howley & D. M. Knipe. Philadelphia: Lippincott Williams & Wilkins.
  62. Williamson, C., Morris, L., Maughan, M. F., Ping, L. H., Dryga, S. A., Thomas, R., Reap, E. A., Cilliers, T., van Harmelen, J. & other authors ( 2003; ). Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses 19, 133–134.[CrossRef]
    [Google Scholar]
  63. Xin, K. Q., Lu, Y., Hamajima, K., Fukushima, J., Yang, J., Inamura, K. & Okuda, K. ( 1999; ). Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clin Immunol 92, 90–96.[CrossRef]
    [Google Scholar]
  64. Yasutomi, Y., Robinson, H. L., Lu, S., Mustafa, F., Lekutis, C., Arthos, J., Mullins, J. I., Voss, G., Manson, K. & other authors ( 1996; ). Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J Virol 70, 678–681.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83501-0
Loading
/content/journal/jgv/10.1099/vir.0.83501-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error